Curadis

Curadis GmbH is a biotechnology company dedicated to developing new drugs and therapeutic concepts for the treatment of hormone-dependent diseases and cancer. CR 1447 is the company's first developed candidate drug, currently in Phase II clinical trials for breast cancer. Curadis GmbH’s business model is based on advancing the company’s innovative therapeutic concepts to the clinical stage for further joint development or licensing with pharmaceutical industry companies.